Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Bristol-Myers Squibb.
The Advances in™ activity format, launched in 2007, has been designed to update and guide oncologists on new and emerging data regarding novel therapeutic agents with the potential to improve treatment, such as molecularly targeted agents, monoclonal antibodies, and immuno-oncology. Advances in™ Immunotherapy: Emerging Agents and the Evolving Standard of Care in Advanced and Metastatic Bladder Cancers will focus on treating bladder cancers with immunotherapy and will consist of video clips of interviews with thought leaders, Drs. Daniel Petrylak and David Quinn. These experts will discuss new data, provide perspective on how evolving concepts may impact future practice, explaining potential application to the clinic.
Instructions For This Activity & Receiving Credit
This educational program is directed toward medical oncologists who treat patients with bladder cancers. Fellows, nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment of bladder cancers are also invited to participate.
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
Disclosure: Grant/Research Support: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Technologies; Consultant: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Technologies. Stock/Shareholder: Bellicum, Tyme Technologies.
David I. Quinn MBBS (Hons), PhD, FRACP, FACP
Medical Director, Norris Cancer Hospital and Clinics
Head, Genitourinary Section
Division of Medical Oncology
Associate Professor of Medicine
Kenneth J. Norris Jr. Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
Los Angeles, CA
Disclosure: Grant/Research Support: Millennium, Genentech, Sanofi; Consultant: Astellas, Bayer, Pfizer, BMS, Merck, EMD Serono, Exelixis, Dendreon, Novartis, Peleton Therapeutics, AstraZeneca; Speaker’s Bureau: NIL; Stock/Shareholder: NIL; Other Support: NIL.
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Feb 10, 2018
February 10, 2018
New York, NY
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Feb 28, 2018
Feb 28, 2018
Feb 28, 2018